Drug Discovery & Development is complex, expensive and time consuming.
The current industry solution is to throw more money at the problem – “Over Capitalization”
This approach has lead to tremendous economic waste and a definition of success by ROI purely for financial gain. The net result is:
The deficiencies in this ecosystem have become the cost burden of the people who need these therapeutic solutions most – – creates an opportunity for iMBP.
Here we introduce iPlatform™
iMBP's proprietary computational approach for in-silico therapeutic discovery and design.
This TechBio solution provides both economic and time saving advantages to drug discovery. Enabled through our partner Amazon Web Services (AWS), iPlatform™ is rapidly evolving and already producing drug asset leads for the expansion of the iMBP drug pipeline.
The development of iPlatform™ is supported in part through a partnership agreement with AWS. To learn more, click the link button below to the company press release.